Patents by Inventor David A. Eavarone

David A. Eavarone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240002537
    Abstract: Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.
    Type: Application
    Filed: November 7, 2022
    Publication date: January 4, 2024
    Applicants: Seagen Inc., The General Hospital Corporation
    Inventors: David A. Eavarone, Jeffrey Behrens, Jillian M. Prendergast, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
  • Publication number: 20240003889
    Abstract: The present invention provides methods of testing anti-STn antibodies for their ability target cancer stem cells by isolating cancer stem cells from cultures, contacting them with anti-STn antibodies being tested, and measuring resulting cell viability.
    Type: Application
    Filed: November 7, 2022
    Publication date: January 4, 2024
    Applicants: Seagen Inc., The General Hospital Corporation
    Inventors: David A. Eavarone, Julie DeSander, Jeffrey Behrens, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
  • Publication number: 20240000962
    Abstract: Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels.
    Type: Application
    Filed: November 7, 2022
    Publication date: January 4, 2024
    Applicant: Seagen Inc.
    Inventors: Daniel T. Dransfield, Jillian M. Prendergast, David A. Eavarone
  • Publication number: 20230331868
    Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include humanized antibodies, derivatives and fragments thereof as well as related compositions and kits. Methods of using glycan-interacting antibodies for treatment and diagnosis are included.
    Type: Application
    Filed: June 14, 2023
    Publication date: October 19, 2023
    Applicant: Seagen Inc.
    Inventors: David A. Eavarone, Jillian M. Prendergast, Jeffrey Behrens
  • Publication number: 20230312747
    Abstract: Methods of detecting, characterizing, and targeting myeloid-derived suppressor cells are disclosed. Some methods include the use of glycan-interacting antibodies, such as anti-STn antibodies. Methods of identifying subjects for treatment with glycan-interacting antibodies are included.
    Type: Application
    Filed: December 6, 2022
    Publication date: October 5, 2023
    Applicant: Seagen Inc.
    Inventors: Jillian M. Prendergast, David A. Eavarone, Patricia Rao
  • Publication number: 20230142697
    Abstract: The present disclosure provides antibodies with T cell-interacting regions and/or glycan-interacting regions. Bispecific antibodies capable of recruiting T cells to cancer cells are also provided, including bispecific antibodies capable of recruiting T cells to cancer cells expressing sialyl Tn (STn). The present disclosure also includes methods for killing cells by targeting them with antibodies having T cell-interacting regions.
    Type: Application
    Filed: June 22, 2022
    Publication date: May 11, 2023
    Applicant: Seagen Inc.
    Inventors: David A. Eavarone, Jeffrey Behrens, Alexey Alexandrovich Lugovskoy
  • Publication number: 20230022411
    Abstract: The present invention provides methods of testing anti-STn antibodies for their ability target cancer stem cells by isolating cancer stem cells from cultures, contacting them with anti-STn antibodies being tested, and measuring resulting cell viability.
    Type: Application
    Filed: March 16, 2022
    Publication date: January 26, 2023
    Applicants: Seagen Inc., The General Hospital Corporation
    Inventors: David A. Eavarone, Julie DeSander, Jeffrey Behrens, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
  • Publication number: 20230029085
    Abstract: Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.
    Type: Application
    Filed: March 16, 2022
    Publication date: January 26, 2023
    Applicants: Seagen Inc., The General Hospital Corporation
    Inventors: David A. Eavarone, Jeffrey Behrens, Jillian M. Prendergast, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
  • Publication number: 20230001007
    Abstract: Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels.
    Type: Application
    Filed: January 4, 2022
    Publication date: January 5, 2023
    Applicant: Seagen Inc.
    Inventors: Daniel T. Dransfield, Jillian M. Prendergast, David A. Eavarone
  • Publication number: 20220259323
    Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include humanized antibodies, derivatives and fragments thereof as well as related compositions and kits. Methods of using glycan-interacting antibodies for treatment and diagnosis are included.
    Type: Application
    Filed: December 1, 2021
    Publication date: August 18, 2022
    Applicant: Seagen Inc.
    Inventors: David A. Eavarone, Jillian M. Prendergast, Jeffrey Behrens
  • Patent number: 11401330
    Abstract: The present disclosure provides antibodies with T cell-interacting regions and/or glycan-interacting regions. Bispecific antibodies capable of recruiting T cells to cancer cells are also provided, including bispecific antibodies capable of recruiting T cells to cancer cells expressing sialyl Tn (STn). The present disclosure also includes methods for killing cells by targeting them with antibodies having T cell-interacting regions.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: August 2, 2022
    Assignee: Seagen Inc.
    Inventors: David A. Eavarone, Jeffrey Behrens, Alexey Alexandrovich Lugovskoy
  • Publication number: 20220057402
    Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.
    Type: Application
    Filed: May 26, 2021
    Publication date: February 24, 2022
    Applicant: Seagen Inc.
    Inventors: Ana Paula Galvao da Silva, Darius Ghaderi, Mai Zhang, Kristan Meetze, Julie DeSander, Jeffrey Behrens, David A. Eavarone, Jillian M. Prendergast
  • Patent number: 11253609
    Abstract: Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: February 22, 2022
    Assignee: Seagen Inc.
    Inventors: Daniel T. Dransfield, Jillian M. Prendergast, David A. Eavarone
  • Patent number: 11028181
    Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include humanized antibodies, derivatives and fragments thereof as well as related compositions and kits. Methods of using glycan-interacting antibodies for treatment and diagnosis are included.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: June 8, 2021
    Assignee: Seagen Inc.
    Inventors: David A. Eavarone, Jillian M. Prendergast, Jeffrey Behrens
  • Publication number: 20210011021
    Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.
    Type: Application
    Filed: February 14, 2020
    Publication date: January 14, 2021
    Applicant: Seattle Genetics, Inc.
    Inventors: Ana Paula Galvao da Silva, Darius Ghaderi, Mai Zhang, Kristan Meetze, Julie DeSander, Jeffrey Behrens, David A. Eavarone, Jillian M. Prendergast
  • Publication number: 20200247902
    Abstract: Methods of detecting, characterizing, and targeting myeloid-derived suppressor cells are disclosed. Some methods include the use of glycan-interacting antibodies, such as anti-STn antibodies. Methods of identifying subjects for treatment with glycan-interacting antibodies are included.
    Type: Application
    Filed: November 17, 2017
    Publication date: August 6, 2020
    Applicant: Seattle Genetics, Inc.
    Inventors: Jillian M. Prendergast, David A. Eavarone, Patricia Rao
  • Publication number: 20200041517
    Abstract: The present invention provides methods of testing anti-STn antibodies for their ability target cancer stem cells by isolating cancer stem cells from cultures, contacting them with anti-STn antibodies being tested, and measuring resulting cell viability.
    Type: Application
    Filed: June 10, 2016
    Publication date: February 6, 2020
    Applicants: Seattle Genetics, Inc., The General Hospital Corporation
    Inventors: David A. EAVARONE, Julie DeSANDER, Jeffrey BEHRENS, Bo R. RUEDA, Rosemary FOSTER, Kristen D. STARBUCK
  • Publication number: 20200000932
    Abstract: Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels.
    Type: Application
    Filed: March 2, 2018
    Publication date: January 2, 2020
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Daniel T. Dransfield, Jillian M. Prendergast, David A. Eavarone
  • Publication number: 20190276541
    Abstract: The present disclosure provides antibodies with T cell-interacting regions and/or glycan-interacting regions. Bispecific antibodies capable of recruiting T cells to cancer cells are also provided, including bispecific antibodies capable of recruiting T cells to cancer cells expressing sialyl Tn (STn). The present disclosure also includes methods for killing cells by targeting them with antibodies having T cell-interacting regions.
    Type: Application
    Filed: November 17, 2017
    Publication date: September 12, 2019
    Inventors: David A. Eavarone, Jeffrey Behrens, Alexey Alexandrovich Lugovskoy
  • Publication number: 20190031780
    Abstract: Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.
    Type: Application
    Filed: January 27, 2017
    Publication date: January 31, 2019
    Inventors: David A. Eavarone, Jeffrey Behrens, Jillian M. Prendergast, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck